IRIS
SCALISE, Giorgio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.860
AS - Asia 4.217
EU - Europa 3.994
SA - Sud America 972
AF - Africa 202
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 5
Totale 17.256
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.713
SG - Singapore 1.454
VN - Vietnam 845
UA - Ucraina 799
BR - Brasile 719
RU - Federazione Russa 687
CN - Cina 596
TR - Turchia 433
IE - Irlanda 415
DE - Germania 395
IT - Italia 345
SE - Svezia 342
HK - Hong Kong 339
DK - Danimarca 292
FR - Francia 269
FI - Finlandia 212
KR - Corea 161
GB - Regno Unito 104
AR - Argentina 98
CI - Costa d'Avorio 83
IN - India 72
MX - Messico 71
BD - Bangladesh 63
CA - Canada 52
EC - Ecuador 43
IQ - Iraq 40
CO - Colombia 39
ID - Indonesia 35
ZA - Sudafrica 34
JP - Giappone 28
IR - Iran 27
PL - Polonia 24
PY - Paraguay 24
MA - Marocco 23
NL - Olanda 21
VE - Venezuela 17
UZ - Uzbekistan 16
BE - Belgio 13
EG - Egitto 13
PH - Filippine 13
PK - Pakistan 13
ES - Italia 12
TN - Tunisia 12
AT - Austria 11
CL - Cile 11
KE - Kenya 10
PE - Perù 9
JO - Giordania 8
MY - Malesia 8
NP - Nepal 8
RO - Romania 8
BG - Bulgaria 7
OM - Oman 7
UY - Uruguay 7
AE - Emirati Arabi Uniti 6
KZ - Kazakistan 6
LT - Lituania 6
SA - Arabia Saudita 6
DO - Repubblica Dominicana 5
PS - Palestinian Territory 5
AU - Australia 4
AZ - Azerbaigian 4
BO - Bolivia 4
CY - Cipro 4
DZ - Algeria 4
BH - Bahrain 3
CG - Congo 3
CM - Camerun 3
CR - Costa Rica 3
ET - Etiopia 3
EU - Europa 3
GT - Guatemala 3
HU - Ungheria 3
IL - Israele 3
MD - Moldavia 3
NO - Norvegia 3
PA - Panama 3
PT - Portogallo 3
SN - Senegal 3
SY - Repubblica araba siriana 3
TT - Trinidad e Tobago 3
AL - Albania 2
BY - Bielorussia 2
CH - Svizzera 2
CZ - Repubblica Ceca 2
EE - Estonia 2
GE - Georgia 2
HR - Croazia 2
KW - Kuwait 2
LY - Libia 2
MU - Mauritius 2
NG - Nigeria 2
RS - Serbia 2
SV - El Salvador 2
TH - Thailandia 2
A1 - Anonimo 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BJ - Benin 1
Totale 17.235
Salva come PNG Salva come JPEG
Città #
Ashburn 1.347
Singapore 877
Jacksonville 784
Chandler 506
Fairfield 491
Dallas 459
Dublin 415
Boardman 371
San Jose 329
Hong Kong 324
Wilmington 288
Ho Chi Minh City 272
Woodbridge 228
Hanoi 218
New York 216
Houston 203
Seattle 191
Moscow 171
Cambridge 168
Lawrence 157
Princeton 157
San Mateo 156
Beijing 149
Ann Arbor 140
Lauterbourg 129
The Dalles 124
Hefei 103
Los Angeles 99
Abidjan 83
Des Moines 82
Turin 63
Milan 61
São Paulo 59
San Diego 52
Buffalo 51
Munich 48
Da Nang 46
Helsinki 29
Orem 29
Turku 28
Haiphong 27
Santa Clara 27
Mexico City 26
Miano 26
London 25
Izmir 23
Chicago 22
Rio de Janeiro 22
Shanghai 22
Tokyo 22
Warsaw 20
Belo Horizonte 18
Denver 18
Council Bluffs 17
Johannesburg 17
Biên Hòa 15
Chennai 15
Guangzhou 15
Montreal 15
Nuremberg 15
Tashkent 15
Wuhan 15
Brasília 14
Dhaka 14
Norwalk 14
Amsterdam 13
Hải Dương 13
Manchester 13
Phoenix 13
Stockholm 13
Atlanta 12
Baghdad 12
Brussels 12
Falls Church 12
Ottawa 12
Redmond 12
Brooklyn 11
Can Tho 11
Columbus 11
Curitiba 11
Mumbai 11
Asunción 10
Guayaquil 10
Jakarta 10
Kilburn 10
Nairobi 10
Ninh Bình 10
Salt Lake City 10
Buenos Aires 9
Bắc Giang 9
Caracas 9
Medellín 9
Ankara 8
Centro 8
Elk Grove Village 8
Frankfurt am Main 8
Guarulhos 8
New Delhi 8
Nha Trang 8
Poplar 8
Totale 10.544
Salva come PNG Salva come JPEG
Nome #
Comparative efficacy of topical versus systemic teicoplanin in experimental model of wound infections 333
Antimicrobial Resistance: A Challenge for the Future 303
Prophylactic efficacy of topical temporin A and RNAIII-inhibiting peptide in a subcutaneous rat pouch model of graft infection attributable to staphylococci with intermediate resistance to glycopeptides 265
RNAIII-inhibiting peptide in combination with the cathelicidin BMAP-28 reduces lethality in mouse models of staphylococcal sepsis 229
Citropin 1.1-treated central venous catheters improve the efficacy of hydrophobic antibiotics in the treatment of experimental staphylococcal catheter-related infection. 208
BisEDT and RIP act in synergy to prevent graft infections by resistant staphylococci. 200
Anticryptosporidial activity of paromomycin. 199
ACTIVITY OF THE NEW ANTIFUNGAL TRIAZOLE, POSACONAZOLE, AGAINST CRYPTOCOCCUS NEOFORMANS 188
Administration of protegrin peptide IB-367 to prevent endotoxin induced mortality in bile duct ligated rats. 182
Tollerabilità metabolica e durevolezza degli schemi antiretrovirali comprendenti nevirapina (Durability and tolerability of long-term nevirapine-based HAART). 175
Cecropin B enhances betalactams activities in experimental rat models of gram-negative septic shock 165
Antiendotoxin activity of antimicrobial peptides and glycopeptides. 154
Epidemiology and microbiology of surgical wound infections. 152
Cathelicidin peptide sheep myeloid antimicrobial peptide-29 prevents endotoxin-induced mortality in rat models of septic shock 148
Comparative efficacies of quinupristin-dalfopristin, linezolid, vancomycin, and ciprofloxacin in treatment, using the antibiotic-lock technique, of experimental catheter-related infection due to Staphylococcus aureus. 148
Amphibian Peptides Prevent Endotoxemia and Bacterial Translocation in Bile Duct-Ligated Rats 147
[Prevalence of Toxocara spp in public playgrounds in a town of Central Italy] 146
[Giardiasis: a parasitic disease of continued topicality. Study of prevalence among a selected adult population] 146
Therapeutic efficacy of intraperitoneal polymyxin B and polymyxin-like peptides alone or combined with levofloxacin in rat models of septic shock 146
A chimeric peptide composed of a dermaseptin derivative and an RNA III-inhibiting peptide prevents graft-associated infections by antibiotic-resistant staphylococci. 142
In vitro activity of amphibian peptides alone and in combination with antimicrobial agents against multidrug-resistant pathogens isolated from surgical wound infection. 141
Antiendotoxin activity of protegrin analog IB-367 alone or in combination with piperacillin in different animal models of septic shock 141
In vitro activity of citropin 1.1 alone and in combination with clinically used antimicrobial agents against Rhodococcus equi. 139
Antiseptic compounds still active against bacterial strains isolated from surgical wound infections despite increasing antibiotic resistance. 138
The antimicrobial peptide BMAP-28 reduces lethality in mouse models of staphylococcal sepsis 138
Interaction of antimicrobial peptide temporin L with lipopolysaccharide in vitro and in experimental rat models of septic shock caused by gram-negative bacteria. 132
In vitro activity of MSI-78 alone and in combination with antibiotics against bacteria responsible for bloodstream infections in neutropenic patients. 132
Efficacy of tachyplesin III, colistin, and imipenem against a multiresistant Pseudomonas aeruginosa strain. 131
Therapeutic efficacy of the magainin analogue MSI-78 in different intra-abdominal sepsis rat models. 131
In vitro activities of tritrpticin alone and in combination with other antimicrobial agents against Pseudomonas aeruginosa. 130
Mupirocin prophylaxis against methicillin-susceptible, methicillin-resistant, or vancomycin-intermediate Staphylococcus epidermidis vascular-graft infection. 128
Cationic peptides combined with betalactams reduce mortality from peritonitis in experimental rat model. 127
Distinctin improves the efficacies of glycopeptides and betalactams against staphylococcal biofilm in an experimental model of central venous catheter infection. 127
Pre-treatment of central venous catheters with the cathelicidin BMAP-28 enhances the efficacy of antistaphylococcal agents in the treatment of experimental catheter-related infection. 126
Temporin A soaking in combination with intraperitoneal linezolid prevents vascular graft infection in a subcutaneous rat pouch model of infection with Staphylococcus epidermidis with intermediate resistance to glycopeptides. 124
Effects of pexiganan alone and combined with betalactams in experimental endotoxic shock 124
Experimental study on the efficacy of combination of alpha-helical antimicrobial peptides and vancomycin against Staphylococcus aureus with intermediate resistance to glycopeptides. 123
[Vascular graft infection by Staphylococcus epidermidis: efficacy of various perioperative prophylaxis protocols in an animal model]. 123
Experimental induction of fluconazole resistance in Candida tropicalis ATCC 750. 122
Comparative activities of cecropin A, melittin, and cecropin A-melittin peptide CA(1-7)M(2-9)NH2 against multidrug-resistant nosocomial isolates of Acinetobacter baumannii. 122
Temporin A alone and in combination with imipenem reduces lethality in a mouse model of staphylococcal sepsis. 122
Single-dose intraperitoneal magainins improve survival in a gram-negative-pathogen septic shock rat model. 122
In vitro activity of the histatin derivative P-113 against multidrug-resistant pathogens responsible for pneumonia in immunocompromised patients. 120
Suppression of drug-resistant Staphylococcal Infections by the quorum-sensing inhibitor RNAIII-inhibiting peptide. 119
RNAIII-inhibiting peptide significantly reduces bacterial load and enhances the effect of antibiotics in the treatment of central venous catheter-associated Staphylococcus aureus infections. 119
RNAIII-Inhibiting Peptide-Loaded Polymethylmethacrylate Prevents In Vivo Staphylococcus aureus Biofilm Formation 118
LL-37 protects rats against lethal sepsis caused by gram-negative bacteria. 118
Interactions of posaconazole and flucytosine against Cryptococcus neoformans. 118
Efficacy of colistin/rifampin combination in experimental rat models of sepsis due to a multiresistant Pseudomonas aeruginosa strain. 117
Efficacy of quinupristin/dalfopristin in preventing vascular graft infection due to Staphylococcus epidermidis with intermediate resistance to glycopeptides. 117
Effects of the antimicrobial peptide BMAP-27 in a mouse model of obstructive jaundice stimulated by lipopolysaccharide 116
In vitro activity and killing effect of the synthetic hybrid cecropin A-melittin peptide CA(1-7)M(2-9)NH(2) on methicillin-resistant nosocomial isolates of Staphylococcus aureus and interactions with clinically used antibiotics. 115
RNAIII-inhibiting peptide enhances healing of wounds infected with methicillin-resistant Staphylococcus aureus. 115
Temporin A is effective in MRSA-infected wounds through bactericidal activity and acceleration of wound repair in a murine model. 115
In vitro activity and killing effect of citropin 1.1 against gram-positive pathogens causing skin and soft tissue infections. 114
Comparative efficacy of quinupristin/dalfopristin, linezolid, vancomycin and ciprofloxacin in the treatment of experimental catheter-related infection due to Staphylococcus aureus using the antibiotic-lock technique 113
In vitro activities of membrane-active peptides alone and in combination with clinically used antimicrobial agents against Stenotrophomonas maltophilia. 113
LL-37 protects rats against lethal gram-negative sepsis. 111
Effect of mono-dose intraperitoneal cecropins in experimental septic shock 111
Temporin A as a prophylactic agent against methicillin sodium-susceptible and methicillin sodium-resistant Staphylococcus epidermidis vascular graft infection. 110
In-vitro activity of polycationic peptides against Cryptosporidium parvum, Pneumocystis carinii and yeast clinical isolates. 110
Prophylactic efficacy of linezolid alone or combined with levofloxacin and vancomycin in a rat subcutaneous pouch model of graft infection caused by Staphylococcus epidermidis with intermediate resistance to glycopeptides. 110
Use of the quorum-sensing inhibitor RNAIII-inhibiting peptide to prevent biofilm formation in vivo by drug-resistant Staphylococcus epidermidis. 110
RNA III inhibiting peptide inhibits in vivo biofilm formation by drug-resistant Staphylococcus aureus. 110
Protective effects of the combination of alpha-helical antimicrobial peptides and rifampicin in three rat models of Pseudomonas aeruginosa infection. 109
In vitro and in vivo activity of aurintricarboxylic acid preparations against Cryptosporidium parvum. 108
Prophylaxis against Staphylococcus aureus vascular graft infection with mupirocin-soaked, collagen-sealed dacron. 108
In vitro activities of tachyplesin III against Pseudomonas aeruginosa. 107
Potential therapeutic role of histatin derivative P-113d in experimental rat models of Pseudomonas aeruginosa sepsis. 106
In vitro effect on Cryptosporidium parvum of short-term exposure to cathelicidin peptides. 106
In vitro activity and killing effect of temporin A on nosocomial isolates of Enterococcus faecalis and interactions with clinically used antibiotics. 105
In vitro susceptibility of dermatophytes to conventional and alternative antifungal agents. 105
Neutralization of endotoxin in vitro and in vivo by Bac7(1-35), a proline-rich antibacterial peptide 104
Electrophoretic karyotyping and antifungal susceptibility patterns of Candida parapsilosis clinical isolates causing deep and superficial fungal infections 104
In-vitro interaction of terbinafine with amphotericin B, fluconazole and itraconazole against clinical isolates of Candida albicans. 102
In-vitro activity of topoisomerase inhibitors against Pneumocystis carinii. 102
In vitro activities of membrane-active peptides against gram-positive and gram-negative aerobic bacteria. 101
RNAIII-inhibiting peptide and/or nisin inhibit experimental vascular graft infection with methicillin-susceptible and methicillin-resistant Staphylococcus epidermidis. 101
In- vitro activity of terbinafine, atovaquone and co-trimoxazole against Pneumocystis carinii. 101
Efficacy of rifampin-levofloxacin as a prophylactic agent in preventing Staphylococcus epidermidis graft infection. 100
In vitro activities of the lipopeptides palmitoyl (Pal)-Lys-Lys-NH(2) and Pal-Lys-Lys alone and in combination with antimicrobial agents against multiresistant gram-positive cocci. 100
Efficacy of treatment with paromomycin, azithromycin, and nitazoxanide in a patient with disseminated cryptosporidiosis. 100
Treatment of Staphylococcus aureus Biofilm infection by the quorum sensing inhibitor RIP 99
Therapeutic efficacy of the polymyxin-like peptide ranalexin in an experimental model of endotoxemia. 99
Pretreatment with the protegrin IB-367 affects Gram-positive biofilm and enhances the therapeutic efficacy of linezolid in animal models of central venous catheter infection. 99
In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens 98
The lipopeptides Pal-Lys-Lys-NH(2) and Pal-Lys-Lys soaking alone and in combination with intraperitoneal vancomycin prevent vascular graft biofilm in a subcutaneous rat pouch model of staphylococcal infection 98
In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species 98
Efficacy of polycationic peptides in preventing vascular graft infection due to Staphylococcus epidermidis. 97
Point prevalence, microbiology and fluconazole susceptibility patterns of yeast isolates colonizing the oral cavities of HIV-infected patients in the era of highly active antiretroviral therapy. 97
Prevalence of intestinal parasites among individuals with allergic skin diseases. 97
Carbapenem-induced resistance to beta-lactams in Pseudomonas aeruginosa. 97
Efficacy of Tachyplesin III, Colistin and Imipenem against Multiresistant Pseudomonas aeruginosa 96
In vitro activity and killing effect of uperin 3.6 against gram-positive cocci isolated from immunocompromised patients. 96
Interactions between triazoles and amphotericin B against Cryptococcus neoformans. 96
In-vitro interactions of itraconazole with flucytosine against clinical isolates of Cryptococcus neoformans. 96
Inhibition of growth of Pneumocystis carinii by lactoferrins alone and in combination with pyrimethamine, clarithromycin and minocycline. 96
Unusual clinical presentation of infection due to Flavimonas oryzihabitans. 96
Polycationic peptides as prophylactic agents against methicillin-susceptible or methicillin-resistant Staphylococcus epidermidis vascular graft infection. 96
In-vitro activity of rifabutin and albendazole singly and in combination with other clinically used antimicrobial agents against Pneumocystis carinii. 95
Totale 12.753
Salva come PNG Salva come JPEG
Categoria #
all - tutte 76.925
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 76.925
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021100 0 0 0 0 0 0 0 0 0 0 0 100
2021/20221.154 88 240 0 51 9 106 45 63 73 194 37 248
2022/20231.684 202 170 135 121 124 180 4 82 487 8 128 43
2023/20241.032 212 18 44 190 200 201 15 7 5 5 25 110
2024/20252.374 280 199 177 113 105 150 263 96 469 103 196 223
2025/20266.686 311 577 592 839 593 404 1.160 707 659 505 80 259
Totale 17.412